In their article, Brown and colleagues report a study of the prevalence of unrecognized primary aldosteronism that is a game changer. The study shows that the single spot measurement of plasma aldosterone concentration, which clinicians have used for decades to screen for primary aldosteronism, is not merely useless but actually misleading. The authors caution readers about the uncertain representativeness of the study population for the U.S. population, but I believe that the findings are generalizable to the United States and elsewhere.
